Physical, psychological and nutritional outcomes in a cohort of Irish patients with metastatic peritoneal malignancy scheduled for cytoreductive surgery (CRS) and heated intrapertioneal chemotherapy (HIPEC): An exploratory pilot study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
09
2020
accepted:
10
11
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
20
1
2021
Statut:
epublish
Résumé
Treatment for peritoneal malignancy (PM) can include cytoreductive surgery (CRS) and heated intrapertioneal chemotherapy (HIPEC) and is associated with morbidity and mortality. Physical, psychological and nutritional outcomes are important pre-operatively. The aim of this pilot study was to investigate these outcomes in patients with PM before and after CRS-HIPEC. Between June 2018 and November 2019, participants were recruited to a single-centre study. Primary outcome was cardiopulmonary exercise testing (CPET) variables oxygen uptake (VO2) at anaerobic threshold (AT) and at peak. Secondary outcome measures were upper and lower body strength, health related quality of life (HRQoL) and the surgical fear questionnaire. Exploratory outcomes included body mass index, nutrient intake and post-operative outcome. All participants were asked to undertake assessments pre CRS-HIPEC and 12 weeks following the procedure. Thirty-nine patients were screened, 38 were eligible and 16 were recruited. Ten female and 6 male, median (IQR) age 53 (42-63) years. Of the 16 patients recruited, 14 proceeded with CRS-HIPEC and 10 competed the follow up assessment at week 12. Pre-operative VO2 at AT and peak was 16.8 (13.7-18) ml.kg-1.min-1 and 22.2 (19.3-25.3) ml.kg-1.min-1, upper body strength was 25.9 (20.3-41.5) kg, lower body strength was 14 (10.4-20.3) sec, HRQoL (overall health status) was 72.5 (46.3-80) % whilst overall surgical fear was 39 (30.5-51). The VO2 at AT decreased significantly (p = 0.05) and HRQoL improved (p = 0.04) between pre and post- CRS-HIPEC. There were no significant differences for any of the other outcome measures. This pilot study showed a significant decrease in VO2 at AT and an improvement in overall HRQoL at the 12 week follow up. The findings will inform a larger study design to investigate a prehabilitation and rehabilitation cancer survivorship programme.
Sections du résumé
BACKGROUND
Treatment for peritoneal malignancy (PM) can include cytoreductive surgery (CRS) and heated intrapertioneal chemotherapy (HIPEC) and is associated with morbidity and mortality. Physical, psychological and nutritional outcomes are important pre-operatively. The aim of this pilot study was to investigate these outcomes in patients with PM before and after CRS-HIPEC.
METHODS
Between June 2018 and November 2019, participants were recruited to a single-centre study. Primary outcome was cardiopulmonary exercise testing (CPET) variables oxygen uptake (VO2) at anaerobic threshold (AT) and at peak. Secondary outcome measures were upper and lower body strength, health related quality of life (HRQoL) and the surgical fear questionnaire. Exploratory outcomes included body mass index, nutrient intake and post-operative outcome. All participants were asked to undertake assessments pre CRS-HIPEC and 12 weeks following the procedure.
RESULTS
Thirty-nine patients were screened, 38 were eligible and 16 were recruited. Ten female and 6 male, median (IQR) age 53 (42-63) years. Of the 16 patients recruited, 14 proceeded with CRS-HIPEC and 10 competed the follow up assessment at week 12. Pre-operative VO2 at AT and peak was 16.8 (13.7-18) ml.kg-1.min-1 and 22.2 (19.3-25.3) ml.kg-1.min-1, upper body strength was 25.9 (20.3-41.5) kg, lower body strength was 14 (10.4-20.3) sec, HRQoL (overall health status) was 72.5 (46.3-80) % whilst overall surgical fear was 39 (30.5-51). The VO2 at AT decreased significantly (p = 0.05) and HRQoL improved (p = 0.04) between pre and post- CRS-HIPEC. There were no significant differences for any of the other outcome measures.
CONCLUSION
This pilot study showed a significant decrease in VO2 at AT and an improvement in overall HRQoL at the 12 week follow up. The findings will inform a larger study design to investigate a prehabilitation and rehabilitation cancer survivorship programme.
Identifiants
pubmed: 33296392
doi: 10.1371/journal.pone.0242816
pii: PONE-D-20-29340
pmc: PMC7725307
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0242816Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Surg. 2009 Jun;249(6):900-7
pubmed: 19474692
Nutr J. 2013 Aug 14;12:118
pubmed: 23941331
PLoS One. 2016 Jun 16;11(6):e0157113
pubmed: 27310615
Clin Nutr. 2017 Jun;36(3):623-650
pubmed: 28385477
Ann Surg. 2007 Mar;245(3):487-94
pubmed: 17435557
Respir Med. 2007 Feb;101(2):286-93
pubmed: 16806873
Eur J Surg Oncol. 2020 Dec;46(12):2292-2310
pubmed: 32873454
J Clin Epidemiol. 2007 Sep;60(9):919-28
pubmed: 17689808
Br J Anaesth. 2004 Jul;93(1):121-8
pubmed: 15121729
J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5
pubmed: 17481516
Ann Surg Oncol. 2020 Oct;27(10):3973-3983
pubmed: 32335752
Crit Rev Oncol Hematol. 2016 Apr;100:209-22
pubmed: 26867984
Dig Surg. 2014;31(4-5):334-40
pubmed: 25471828
J Cardiothorac Surg. 2011 Aug 15;6:98
pubmed: 21843340
Gastric Cancer. 2016 Jul;19(3):1008-15
pubmed: 26466832
Surgery. 2014 Feb;155(2):211-6
pubmed: 24331759
Nutr Res Rev. 2016 Dec;29(2):268-280
pubmed: 27955721
J Am Coll Cardiol. 2017 Sep 26;70(13):1618-1636
pubmed: 28935040
Eur J Surg Oncol. 2020 Jan 30;:
pubmed: 32063398
Expert Rev Cardiovasc Ther. 2014 Dec;12(12):1439-53
pubmed: 25418758
J Clin Oncol. 2004 Aug 15;22(16):3284-92
pubmed: 15310771
Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):358-368
pubmed: 30271817
J Phys Ther Sci. 2019 Jan;31(1):75-78
pubmed: 30774209
Nutr Rev. 2016 Dec;74(12):737-748
pubmed: 27864535
PLoS One. 2016 Sep 9;11(9):e0162737
pubmed: 27611076
Am J Phys Med Rehabil. 2019 Oct;98(10):888-896
pubmed: 31090551
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Ann Surg Oncol. 2012 Jul;19(7):2186-94
pubmed: 22395983
Clin Colorectal Cancer. 2012 Sep;11(3):167-76
pubmed: 22397952
J Gastrointest Oncol. 2016 Feb;7(1):87-98
pubmed: 26941987
Anesthesiology. 2015 Dec;123(6):1455-72
pubmed: 26248016
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
Indian J Surg Oncol. 2016 Jun;7(2):208-14
pubmed: 27065711
Br J Anaesth. 2016 Feb;116(2):177-91
pubmed: 26787788
J Appl Physiol (1985). 1986 Jun;60(6):2020-7
pubmed: 3087938
Ann Surg. 2019 Sep;270(3):493-501
pubmed: 31318793
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
J Gastrointest Surg. 2018 May;22(5):884-893
pubmed: 29363016
PLoS One. 2014 Dec 04;9(12):e113637
pubmed: 25474696
Psychooncology. 2017 Aug;26(8):1070-1079
pubmed: 27643482
Ann Surg Oncol. 2013 Jan;20(1):226-32
pubmed: 22868919
J Hand Surg Am. 1984 Mar;9(2):222-6
pubmed: 6715829
Anaesthesia. 2019 Jan;74 Suppl 1:36-42
pubmed: 30604423